RESOURCES
-
-
-
November 04, 2025
Advancing Novel Breast Cancer Drug Development with HER2-ADC Resistance Models
According to data from the World Health Organization (WHO), breast cancer is the second most commonly diagnosed cancer globally, after lung cancer, and remains the leading cause of cancer incidence and mortality among women.
-
-
-
-
October 27, 2025
Evaluating CD20 Antibody Efficacy Using BAFF/CD20 Dual-Target Humanized Mice
B-cell–driven autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis are characterized by overactive B-cell signaling, autoantibody production, and chronic inflammation. CD20, a B-cell surface marker critical for activation and differentiation, has emerged as a key therapeutic target in these disorders. Antibodies that deplete B-cells, such as Rituximab, have demonstrated strong clinical efficacy, but preclinical evaluation requires models that faithfully replicate human immune biology.
-
-
-
-
October 12, 2025
Accelerating Anti-Myopathy Drug Discovery: A Dexamethasone-Induced Sarcopenia Model for Preclinical Evaluation
Sarcopenia, the progressive loss of skeletal muscle mass and function, is a major contributor to frailty, falls and chronic morbidity in aging populations. Beyond physical decline, sarcopenia increases susceptibility to cardiovascular, respiratory, and cognitive disorders, significantly impacting the quality of life and mortality. Despite its growing prevalence, no FDA-approved pharmacological therapy currently exist for sarcopenia. Preclinical animal models are essential for understanding disease mechanisms and evaluating therapeutic candidates, but traditional models such as aged or genetically modified mice require long study timelines and often show high variability.
-
-
-
-
September 29, 2025
Modeling Hypertrophic Cardiomyopathy: Next-Generation Mouse Models for Translational Research
Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart disease, affecting up to 1 in 200 individuals worldwide. Its main characteristics include thickening of the ventricular walls and impaired cardiac function, leading to progressive dyspnea, angina pectoris, heart failure, atrial fibrillation, and sudden cardiac death. While current treatments can alleviate symptoms in some patients, they fail to address the underlying pathophysiological mechanisms of the disease. Novel therapeutic strategies targeting sarcomeric proteins have raised hope, but there remains an urgent need for preclinical models that replicate HCM pathology.
-
-
-
-
September 28, 2025
Shaping the Future of In Vivo Genomic Editing: GemPharmatech’s Next-Generation NCG Portfolio
For decades, gene therapy relied heavily on ex vivo modification. Patient primary cells were collected , engineered in the lab, and reinfused back into patients. This method produced major breakthroughs, but it came at a high cost: complex logistics, high treatment expenses, and risks associated with conditioning regimens. Moving from ex vivo to in vivo genomic engineering is one way to circumvent these challenges. Therapies that directly edit the patient cells inside the body would eliminate the need forcell harvest and conditioning, dramatically simplifying the treatment and making gene therapy more widely accessible.
-
-
-
-
August 25, 2025
From Lab to Clinic: How RXFP1-Humanized Mice are Paving the Way for Next-Generation Cardiovascular Therapeutics
The relaxin receptor RXFP-1 plays a pivotal role in cardiovascular health. Widely expressed in the heart, kidneys, and blood vessels, RXFP-1 is activated by relaxin, an endogenous heterodimeric insulin-like peptide. Beyond regulating cardiovascular functions such as renal blood flow, relaxin exerts anti-fibrotic, anti-inflammatory, and angiogenic effects, positioning the RXFP-1 pathway as a promising therapeutic target for conditions including heart failure and liver fibrosis.
-
-
-
-
August 20, 2025
Unlocking the Potential of Antibody-Drug Conjugates: GemPharmatech’s Comprehensive In Vitro Evaluation Platform
Antibody-drug conjugates (ADCs) represent a rapidly advancing therapeutic class for both solid tumors and hematological malignancies. Unlike conventional monoclonal antibodies, ADCs combine a tumor-targeting antibody with a highly potent cytotoxic payload, enabling selective drug delivery to cancer cells. At GemPharmatech, we provide integrated end-to-end preclinical solutions to support ADC development. These solutions center around an advanced in vitro platform as well as in vivo capabilities to support every step of ADC functional assessment
-
-
-
-
August 06, 2025
Advance Psoriatic Arthritis Drug Discovery with a Validated Preclinical Model for JAKi and Dexamethasone Testing
August is Psoriasis Awareness Month, a time to raise awareness for psoriasis, a chronic immune-mediated skin condition marked by erythematous plaques, scaling, and dysregulated keratinocyte proliferation.However, the burden can extend beyond the skin. Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA), a progressive inflammatory disease affecting the joints.
-
-
-
-
July 16, 2025
Advancing Alzheimer's Research at AAIC 2025: Discover GemPharmatech's Cutting-Edge AD Mouse Models
The Alzheimer's Association International Conference (AAIC 2025) is the premier global forum for groundbreaking research in Alzheimer's disease (AD) and dementia. As a leader in preclinical models, GemPharmatech is proud to showcase our advanced AD mouse models at this year's conference. Join us to explore how our innovative tools can accelerate your research and drive the next wave of therapeutic breakthroughs.
-